A pilot trial at the University of Missouri found that a month of daily low-dose rapamycin raised blood flow in the brains of healthy middle-aged adults who carry APOE4, the best-known gene variant tied to Alzheimer’s risk. Volunteers without the variant took the same drug and showed no comparable change. The researchers frame the result as an early signal about who might benefit, not evidence that the drug protects memory.
The tech news worth your time: 400,000+ professionals from Google, Apple and OpenAI read Techpresso, a daily email with the most interesting tech news and insights.
We may earn a commission if you sign up.
Ai-Ling Lin, the School of Medicine professor who led the work, said the project is an example of precision medicine, aimed at finding which people gain the most from a drug already approved for other uses. Rapamycin is best known as a medicine given to prevent organ transplant rejection, and its use here remains investigational.
A nine-carrier pilot at 1 milligram a day
The university’s own announcement on Mizzou’s research news site describes healthy adults aged 45 to 65, none with Alzheimer’s symptoms, who took a low daily dose of rapamycin for four weeks. The paper itself, an accelerated-publication article in the Journal of Cerebral Blood Flow & Metabolism, is titled as a pilot single-arm trial and is indexed under its DOI record. Single-arm means every participant received rapamycin, so the comparison is between genotypes rather than against a placebo group.
Numbers come from a secondary write-up. Neuroscience News reported that 23 people completed the study, nine of them APOE4 carriers and 14 non-carriers, taking 1 milligram daily. Carriers showed cerebral blood flow increases above 15% across several brain regions, while non-carriers showed no significant change, according to that account. Mizzou’s release gives neither the headcount nor the milligram dose, so those two figures rest on the secondary report.
The paper’s full name goes further than the blood-flow result. It says rapamycin also modulated metabolic, inflammatory and microbiome profiles in these healthy middle-aged APOE4 carriers, and Neuroscience News adds that metabolic and inflammatory measures improved with minimal adverse effects. No figures for those secondary measures appear in the Missouri announcement, so they are best read as listed endpoints, not as findings with a size. The author list runs to 17 names, with Lin as senior author, which is typical of an imaging study that needs radiology, genetics and microbiome expertise under one roof.
Women carriers showed the largest gain
Within the carrier group, women improved the most. Lin said in the university announcement that females with APOE4 saw the greatest improvement in brain blood flow, and she pointed out that nearly two-thirds of people living with Alzheimer’s are women. A ScienceDaily summary of the Missouri release carries the same subgroup finding without any effect sizes, and none of the coverage reports how many women were among the nine carriers.
That matters for interpretation. A subgroup of a few people inside a group of nine cannot support a firm claim about sex differences, and the researchers did not present it as one. It reads best as a lead for a larger, controlled study that enrolls enough women to test the pattern.
APOE4 carriers and the blood-flow target
The National Institute on Aging’s genetics fact sheet says about 15% to 25% of people carry one copy of the APOE4 allele and 2% to 5% carry two, and that having two copies is associated with higher Alzheimer’s risk than having one. Plenty of carriers never develop the disease, which is part of why researchers want to know whether an early intervention could matter for those who would.
Lin’s earlier work in mice suggested rapamycin could slow brain aging and improve blood flow in animals carrying APOE4. Mouse results do not establish the same effect in people, which is the gap this trial begins to probe, and brain blood flow is the measure it chose to read out after the short course.
Lin framed the larger aim in the university announcement as slowing down aging in the brain for the people most at risk. That goal explains the choice of volunteers: healthy adults between 45 and 65 who had no symptoms, a window in which any preventive approach would have to work if it works at all. It also explains why the researchers stratified by genotype instead of enrolling an unselected group, since a drug that helps only carriers would be diluted to nothing in a general sample.
What four weeks cannot show
Local television coverage on FOX 35 Orlando repeated the researchers’ own caution: the study did not test whether rapamycin prevents or delays Alzheimer’s disease, and more research is needed to learn whether higher blood flow translates into lasting brain health. The outcome was a scan measure, not a memory test, and four weeks is far too short to see cognitive decline or its prevention.
The open question is durability and safety over longer periods, since rapamycin is an immunosuppressant in its transplant use. A trial with a placebo arm, more carriers, and cognitive testing would be the natural next step. Neither Mizzou’s announcement nor the secondary reports name a funder or a follow-up trial, so what comes next is still unannounced.
This article was produced with the assistance of AI and reviewed by Morning Overview editors prior to publication.
The tech news worth your time: Subscribe to Techpresso →
We may earn a commission if you sign up.
More from Morning Overview
- Hurricane Hunter radar shows four warning signs that a tropical cyclone is about to strengthen, a University of Miami study found
- Tropical Storm Rachel is dumping up to 12 inches on four Mexican states on its way to major hurricane strength
- The FTC says Lens.com doubled the price shoppers saw in Google ads
- Common allergy, bladder and sleep pills tied to sharply higher dementia odds
